Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024 Psychedelics Investing
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil Pharmaceutical Investing
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim in Early 2025 Pharmaceutical Investing
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis Geography